Scimitar Equity, LLC is an independent equity research firm focused on providing value-added intelligence and insightful investment conclusions on emerging companies demonstrating real progress toward their vision while meeting quarterly expectation.
Aastrom (ASTM) New Analyst Review, Key Catalysts and Milestones
Aastrom Biosciences (ASTM) develops autologous cellular therapies for the treatment of severe and chronic cardiovascular diseases.
Click and Read: http://www.scimitarequity.com/upload/ASTM-catalysts-milestones308163.pdf
ASTM has retained all commercial rights to products in both DCM and CLI for future partnering initiatives which are on-going. The potential to partner ixmyelocel-T for CLI in the US, outside the US, or both, is significant and highly probable. In addition, ASTM has a program in late stage development for cardiac applications in dilated cardiomyopathy (DCM), the most severe form of heart failure.
The Bottom Line: ASTM’s stock is held at a low share price as compared to its P3 status, pending catalysts, completed milestones and valuation. On-going execution offers upside in the near and long-term. However, the share pricing remains challenging based on market volatility, cash positions and negative sentiment. It is believed the treatment has a very good chance to reach the market by 2015 and that it should be well accepted by patients and physicians. ASTM’s leading therapeutic and clinical position is further enhanced by speculation and probability that Pluristem (PSTI) is shopping <hoping to sell> its CLI platform to alleviate a long clinical development process. PSTI is a much earlier stage in its development program, which provides ASTM, a significant advantage given its later stage.
Register here to be notified of future Scimitar Equity articles.
